Proviron is an oral androgen preparation which has only a slight central inhibitory effect and, consequently, no restrictive effect on testicular function. Each tablet contains 10 mg mesterolone.
Mesterolone (Proviron) has androgenic properties. Early studies suggested oral mesterolone did not usually suppress gonadotrophins or endogenous testosterone production. A later single dose study suggests there may be a central suppression effect at doses of 75-100 mg daily. The chemical name for mesterolone is 17 beta-Hydroxy-1 alpha-methyl-5 alphaandrostan-3-one.
Following oral ingestion mesterolome is rapidly and almost completely absorbed in a wide dose range of 10 - 100 mg. Thereafter drug levels in serum decrease with a terminal half-life of 12 13 hours. Mestorelone is bound to serum proteins by 98%. Binding to albumin accounts for 40% and binding to SHBG to 58%.
Indications and usage:
Androgen deficiency or male infertility when associated with primary or secondary male hypogonadism.
Reduced efficiency in middle and advanced age •
Complaints attributable to androgen-deficiency, such as reduced efficiency, easy fatigability, lack of concentration, weak memory, disturbances of libido and potency, irritability, disturbances of sleep, depressive moods, and general vegetative complaints, can be overcome or improved by the use of Proviron tablets.
Potency disturbances •
Potency disorders based on an androgen deficiency are eliminated by administration of Proviron. If other factors are the sole cause or if they contribute to the disorders, Proviron may be administered in support of other therapeutic measures.
Growth, development and function of androgen-dependent target organs are stimulated by Proviron. It promotes development of secondary male sex characteristics in cases of prepuberal androgen-deficiency. Proviron eliminates deficiency symptoms in cases where a loss of gonadal function has occurred postpuberally.
Oligozoospermia and deficient Leydig-cell secretion may be the cause of infertility. With Proviron, sperm count and sperm quality as well as the fructose concentration in the ejaculate can be improved or normalized, thus increasing the chances of procreation.
Dosage and administration:
The tablets should be swallowed whole with some liquid.
The following dosages are recommended:
2-3 tablets of 10mg taken three times per day.
In the case of bodybuilders and athletes, Proviron is normally used between 50 – 150mg per day to either control Estrogen levels, reduce water retention (caused by estrogen), or to increase fertility following the conclusion of a cycle.
According to the type and severity of the complaints, the dose for further treatment is to be adjusted to individual requirements. Continuous treatment over a period of several months is recommended.
Warnings and precautions:
Androgens are not suitable for enhancing muscular development in healthy
individuals or for increasing physical ability.
Risk of carcinoma
The occasionally expressed fear that prostatic carcinoma can be induced by the use of androgens is unfounded. Androgens have no carcinogenic action. Observations made over many years have shown that the risk of carcinoma in men treated with androgens was no greater than in an untreated control group. Specific studies of male patients under long-term and high-dosed therapy with testosterone produced no signs of prostatic carcinoma and, hence, no evidence that the exogenous supply of testosterone activates any atypical cells which may be present.
The regular check-ups during the therapy failed to reveal a single case of carcinoma among patients with prostatic adenoma, whose complaints were favourably influenced by Proviron.
Since androgens can exacerbate a clinically manifest carcinoma of the prostate, malignant tumours of the prostate must be ruled out before the start of Proviron treatment. As in prophylactic examinations of men, regular rectal and - if required to confirm the diagnosis - biopsy examinations must be carried out during the therapy.
In rare cases, benign, and in even rarer cases, malignant liver tumours leading in isolated cases to life-threatening intra-abdominal haemorrhage have been observed after the use of hormonal substances such as the one contained in Proviron. A liver tumour should be included in the differential-diagnostic considerations if severe upper abdominal complaints, a liver enlargement or signs of an intra-abdominal haemorrhage occur. If necessary, the preparation must be withdrawn.
None recorded so far.
Pregnancy and lactation:
None recorded so far.
Proviron is well tolerated even as regards liver function. Laboratory tests conducted during high-dosed and long-term treatment produced no evidence for an injurious effect. If, in individual cases, frequent or persistent erections occur, the dose should be reduced or the treatment discontinued in order to avoid injury to the penis.
There have been no reports of acute overdosage with anabolics.
Store in cool dry place below 30℃. Protect from light.